Journal of Cancer Research and Therapeutics

CASE REPORT
Year
: 2021  |  Volume : 17  |  Issue : 1  |  Page : 276--278

First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor


Angelika Bickel1, Stefan Diem1, Lukas Flatz2, Björn Stinn3, Marco Siano1 
1 Department of Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
2 Department of Dermatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
3 Department of Radiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

Correspondence Address:
Marco Siano
Department of Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen
Switzerland

Until recently, standard treatment for advanced melanoma comprised basically dacarbazine and interleukin-2, leading to low response rates and significant toxicity. These days, new treatments such as immunotherapy (anti-CTLA4 and anti-PD1 antibodies) and targeted therapy with BRAF/MEK-inhibitor combinations for patients harboring a BRAF mutation are available. In BRAF wild-type patients harboring an NRAS mutation, not fit for immunotherapy treatment options are still dismal. We describe an 84-year-old patient with widespread metastatic melanoma. He presented in July 2015 with a cerebral hemorrhage under anticoagulation for atrial fibrillation. Computed tomography revealed extensive metastatic disease (liver, lung, bones, lymph nodes, heart, and brain). Molecular testing was negative for BRAF but showed the presence of an NRAS mutation in exon 3 (pQ61K [c.181C>A]). The patient received as first-line treatment two cycles of cobimetinib showing a good partial remission and manageable side effects.


How to cite this article:
Bickel A, Diem S, Flatz L, Stinn B, Siano M. First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor.J Can Res Ther 2021;17:276-278


How to cite this URL:
Bickel A, Diem S, Flatz L, Stinn B, Siano M. First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor. J Can Res Ther [serial online] 2021 [cited 2021 May 9 ];17:276-278
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2021;volume=17;issue=1;spage=276;epage=278;aulast=Bickel;type=0